EMEKA MADU: Open Payments
NPI 1275003824 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,994 in 85 payments from 18 companies in 2025. Trend: 2023 $73 · 2024 $965 · 2025 $2,994
Food & beverage: $1,966Travel & lodging: $1,028
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 11 | $1,328 |
| Merck Sharp & Dohme LLC | 8 | $212 |
| Alnylam Pharmaceuticals Inc. | 4 | $207 |
| Amgen Inc. | 14 | $154 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $154 |
| PFIZER INC. | 7 | $138 |
| Novartis Pharmaceuticals Corporation | 5 | $119 |
| E.R. Squibb & Sons, L.L.C. | 5 | $110 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $109 |
| Actelion Pharmaceuticals US, Inc. | 5 | $108 |
Products named: CARDIOMEMS, AMVUTTRA, REPATHA, JARDIANCE, WINREVAIR, ELIQUIS, LEQVIO, Kerendia.
Industry payments across NV — which companies pay providers there.
